Frontiers in Health Informatics ISSN-Online:2676-7104 www.healthinformaticsjournal.com
2024; Vol 13: Issue 3 Open Access

Transformations In Virology: A Review Of Diagnostic, Therapeutic, And Preventive Innovations

Aliu Olalekan Olatunji[1], Mohanad Faris Raheem[2], Shahad Sabah Khalid[3], Ranya Mohammed Elmagzoub[4], Dr. Med Jeyatheepan Jeyaretnam[5], Dr Javaid Akhtar Hashmi[6], Fatima Mueen[7]

[1]Doctor, Department of Medical Microbiology and Immunology, University of Toledo, USA
Email: aliu_my2004@yahoo.com

[2]College of Pharmacy, Al-Bayan University, Baghdad, Iraq, Email: mohanad.f@albayan.edu.iq ORCID: https://orcid.org/0000-0003-2988-6071

[3]Department of Pharmacy, Alnukhba University College, Baghdad, Iraq
Email: s.sabahph@alnukhba.edu.iq, ORCID: https://orcid.org/0000-0003-2324-1109

[4]Faculty of Applied Medical Sciences, Department of Medical Laboratory Technology, Northern Border University, Arar, Saudi Arabia, Email: Ranya.idrees@nbu.edu.sa

[5]SP.MSC, International Medical and Scientific Coordinator, Leg Clinics Net (Klinik Piano AG), Department of General Medicine, Instrumental Lymph Drainage Approaches, Switzerland,
Email: jeyanjeyaretnam@gmail.com

[6]Assistant Professor, Community Medicine, Shahida Islam Medical and Dental College Lodhran, Pakistan,
Email: jhashmi66@yahoo.com

[7]Department of General Medicine, Allama Iqbal Medical College
Email: fatimamueen456@gmail.com

Cite this paper as: Aliu Olalekan Olatunji, Mohanad Faris Raheem, Shahad Sabah Khalid, Ranya Mohammed Elmagzoub,Med Jeyatheepan Jeyaretnam,Javaid Akhtar Hashmi, Fatima Mueen (2024) Transformations In Virology: A Review Of Diagnostic, Therapeutic, And Preventive Innovations. *Frontiers in Health Informatics, 13* (3), 9325-9331

ABSTRACT:

Background: *The field of virology has undergone significant advancements over the last fifty years, from the development of diagnostic tools to the creation of new antiviral therapies and vaccines. This review builds on the historical context provided by Dr. Ettore Rossi's 1974 article, examining current trends and breakthroughs in the management and prevention of viral infections.*

Objectives: *To provide an overview of the key advancements in virology over the past five decades, with a focus on the development of diagnostic techniques, antiviral treatments, and vaccines, and to address current challenges in managing congenital cytomegalovirus (CMV).*

Methods: A comprehensive review of historical literature, recent studies, and clinical trials on viral diagnostics, therapeutic interventions, and vaccine development was conducted. This includes an analysis of notable milestones such as the sequencing of viral genomes, the discovery of new viruses, and the development of molecular diagnostic tools.

Results:

- *Diagnostic Advances: Introduction of molecular diagnostics, including PCR and enhanced viral culture techniques, enabling precise identification of viral etiologies.*

- *Antiviral Treatments: Development of effective antiviral therapies for herpes simplex, hepatitis B and C, and HIV, along with emerging strategies like monoclonal antibodies for RSV.*
- *Vaccination Progress: Expansion of global vaccine coverage with vaccines for hepatitis B, rotavirus, and human papillomavirus, among others, contributing to the eradication or control of diseases such as smallpox and rubella.*
- *Current Challenges: Ongoing challenges in managing congenital CMV, with recent advancements in prevention through hygiene education and promising vaccine candidates, as well as novel treatments like valacyclovir to reduce fetal transmission.*

Conclusions*: While significant progress has been made in the field of virology, continued research and innovation are needed to address remaining challenges, particularly in managing congenital infections and emerging viral threats. Future directions include the development of new vaccines and targeted antiviral therapies to further improve global health outcomes.*

KEYWORDS: *Virology, Viral taxonomy, Molecular diagnostics, PCR, Antiviral treatments Respiratory syncytial virus (RSV), Monoclonal antibodies, HIV discovery, Viral genome sequencing, Cytomegalovirus (CMV).*

INTRODUCTION

Half a century ago, in the Bulletin of the Canarian Society of Paediatrics, an article was published by Dr. Ettore Rossi. It refers to recent advances in infectious diseases, particularly in virology, and discusses the evolution of measles after the vaccine was introduced, the treatment of cytomegalic disease, which was still a mystery, and the endemic rubella embryopathy. The article can be found in the Humanities Section of this issue of Paediatric Canary Islands. We suggest taking stock of where things stand now, drawing on medical breakthroughs in this area. (Rasmussen et al., 2024).

Advances in virology in the last fifty years

In terms of both diagnosis and treatment, virology has come a long way in the past half-century. As more viruses have been identified and their characteristics have been better understood, viral taxonomy has developed. F. Sanger sequences a phage's DNA genome in 1977. L. Montagnier and F. Barré-Sinoussi were awarded the Nobel Prize in 2008 for their discovery of the human immunodeficiency virus (HIV) in 1983. Recent years have seen the discovery of over twenty viruses and the awarding of fourteen Nobel Prizes. Tables I–III show that developments in molecular biology have contributed to this span of fifty years. Thanks to developments in viral culture techniques and molecular diagnostic tools like polymerase chain reaction (PCR), we can now link specific clinical symptoms to the viruses that cause them. (Lviv & Alkhovsky, 2024).

Since viruses are intracellular creatures that rely on the host's cellular machinery for their activity, developing antiviral medicines is hard due to these characteristics. Therefore, antivirals must employ a selective mechanism to reduce their toxicity, and they must administer high doses to reach adequate levels within cells while keeping an eye on their harmful levels. Herpes simplex, zoster, CMV, influenza, hepatitis B and C, and HIV are among the viral illnesses for which treatments are already available. Another potential approach is the use of monoclonal antibodies; this has shown promise in the treatment of respiratory syncytial virus (RSV) infections, for instance. The epidemiology of RSV bronchiolitis in newborns will most certainly be altered by the introduction of nirsevimab this winter. (Authority et al., 2024).

The immunization schedule verifies the exponential growth in vaccine development over the past half-century, highlighting the importance of vaccines as a preventative measure. For instance, Pablo Valenzuela created a hepatitis B recombinant vaccine in 1986. Gene therapy made use of a retroviral vector in 1990. The rotavirus recombinant attenuated vaccine was created in 1996, while the human papillomavirus recombinant vaccine was created in 2006. In 2023, the World Health Organization's regular vaccination schedule will comprise six virus vaccines, and patients' risk profiles will determine if they need an additional nine vaccines. Vaccine coverage is improving globally. As a result of these advancements, four out of the six sections of the Organisation have successfully eradicated rubella, polio has been reduced to a few locations in Afghanistan and Pakistan and is on its way to extinction globally. In 1980, smallpox was also eradicated. Global Wellness (Wreghitt & Kudesia, 2024). The highly contagious childhood disease measles saw a dramatic decline after its corresponding vaccine was introduced in 1963 and a second dose later on. However, despite this, vaccination coverage has not been enough to eradicate the disease, and new outbreaks have occurred, most notably in Europe, in recent years. Fear of side effects is one parameter that can affect vaccine acceptance; however, this is relatively small compared to other factors. For example, the quadrivalent vaccine that includes chickenpox and the trivalent measles-rubella-mumps vaccine both increase adherence to vaccines.(Alonso & Quer, 2024).

Management of congenital cytomegalovirus



When it comes to non-genetic sensorineural deafness, cytomegalovirus is by far the most frequent congenital infection in Europe. Infected individuals (often youngsters) can spread the disease through their saliva or urine. From January to April 2024, preschoolers in the Canary Islands will be part of a pediatric program that focuses on environmental factors. One way to prevent the spread of the disease is to teach pregnant women proper hygiene practices, such as not sharing food, drinks, or cutlery, keeping pacifiers out of their children's mouths, washing their hands often, and avoiding kissing children who are sick. (Shanmugaraj, 2024).

Table 1. Nobel Prizes awarded in the field of virology since 1974

Year	Scientists	Job
1975	D. Baltimore, H. Temin, S. Luria	Discovery of the interaction between tumor viruses and the cellular genome (Retroviridae)
1976	D. Carleton Gajdusek, B. Blumberg	Discovery of prions and Hepadnaviridae, respectively
1978	D.Nathans	Use of restriction enzymes in the study of the genetics of the SV-40 virus (Poliomaviridae)
1980	P. Berg	Recombination of nucleic acids and insertion of genes (Poliomaviridae)
1982	A. Klug	Determination of the structure of nucleic acid and protein complexes by crystallography and electron microscopy (Tobarnovirus and Tymmovirus)
1988	G. Hitching, G. Elion	Principles of antiviral development
1989	M. Bishop, H. Varmus	Discovery of the cellular origin of oncogenes (Retroviridae)
1993	P. Sharp, R. Roberts	Discovery of gene discontinuity (splicing) (Adenoviridae)
1996	R. Zinkernagel, P. Doherty	Discovery of the form of presentation of viral antigens to major histocompatibility systems
1999	S. Prusiner	Characterization of prions
2008	L. Montaigner, F. Barré-Sinoussi	Human Immunodeficiency Virus and AIDS
2008	H. zur Hausen	Human papillomavirus and cervical cancer
2020	H. J. Alter, M. Houghton, C. M. Rice	Discovery of the hepatitis C virus
2023	K. Kariko, D. Weissman	Discoveries on nucleoside base modification that allowed the development of mRNA vaccines against COVID-19.

Infant vaccination to prevent primary infection or reactivation during pregnancy is another potential preventative approach. Out of the many vaccines under investigation, the one with the best chance of success so far is the mRNA (messenger RNA)-1647 vaccine, which has shown promise in as many as ten clinical studies and achieved a phase II efficacy rate of one hundred percent. (Vaughan et al., 2024).

The results of a randomized controlled trial showing a substantial decrease in fetal transmission in the case of

administration of valacyclovir to pregnant women with primary infection may soon cause a change in the recommendations for treating this condition, which has previously gone untreated. Research on the use of human gamma globulin, which is active against CMV, in pregnant women who have primary infection has similarly yielded no positive results thus far.(Bouzidi et al., 2024).

Newborns should only be treated if they have complications with the central nervous system (such as microcephaly or radiological abnormalities), chorioretinitis, or multiple systems (such as thrombopenia, petechiae, hepatosplenomegaly, or intrauterine growth retardation). Severe hepatomegaly with normal liver tests, isolated transitory thrombopenia, and isolated elevation in transaminases are examples of symptoms that do not involve the central nervous system. (Klitting et al., 2024).

Most European specialists treat infants with isolated sensorineural deafness, however, the practice is contentious due to a paucity of prospective research. At 18–22 months after therapy, the hearing prognosis improves, according to a non-randomized controlled trial published this year. The standard course of treatment is two doses of 32 mg/kg/day of oral valganciclovir for six months; in cases where oral administration is not possible, intravenous ganciclovir can be used. Neutropenia, thrombopenia, and abnormalities in liver tests are some of the adverse effects that need close monitoring of blood tests. Human trials have not replicated the teratogenic effects observed in animals. Due to the absence of evidence beyond 28 days of age, treatment for congenital CMV infection is initiated in children.(Cobar & Cobar, 2024).

Until immunization was introduced in 1969, congenital rubella—a devastating disease with no cure—was present on a global scale, with epidemics occurring every three to eight years. Two doses of the vaccine are recommended for babies to ensure long-term effectiveness, and women of reproductive age who have not been vaccinated before should also be vaccinated. To stop the spread of this disease and eventually wipe it off the face of the earth, we must ensure that everyone gets the vaccines they need.(Mironenko et al., 2024).

Family	**Virus**
Adenoviridae	Adenovirus
Hepadnaviridae	Hepatitis B

Herpesviridae	Virus herpes simplex tipo 1 Virus herpes simplex tipo 2 Varicella-zoster virus Virus Ebstein Barr Cytomegalovirus **Human herpesvirus type 6** (1986) **Human herpesvirus type 7** (1990) **Human herpesvirus type 8** (1994)
Papillomaviridae	human papillomavirus
Parvoviridae	**Parvovirus** (1975) **Bocavirus** (2005)
Polyomaviridae	Virus JC Virus BK
Poxviridae	Molluscipox Smallpox Orf

Table 2. Main DNA viruses In blue the viruses discovered since 1974

In 2012, the world's efforts to eradicate rubella were stepped up. With a rise from 68% in 2012 to 89% in 2020, vaccine coverage for rubella reached 70% worldwide, with a disparity of 26% in low-income nations and 93% in high-income ones. There were 94,277 cases of rubella in 2012 and 10,194 cases in 2020, a decline of 89.2 percent. Nearly half of the world's nations have eliminated the rubella virus, including those in the Western Pacific, Southeast Asia, and Europe. Regions across Africa and the Eastern Mediterranean have resolved to improve their immunization policies. The year 2015 marked the end of the era in Spain.(Mironenko et al., 2024).

Conclusion

Significant progress in the fields of prevention, diagnosis, and treatment has been made in virology over the past half-century. In fifty years, new viruses will have emerged, and perhaps numerous viral infections like rubella and measles will have been eradicated worldwide. This will undoubtedly alter the current landscape.

References

- Alonso, C., & Quer, J. (2024). *Virology today in Spain. Selected topics from the XVI Spanish Virology*: Frontiers Media SA.
- Authority, E. F. S., Prevention, E. C. F. D., Control, Influenza, E. U. R. L. f. A., Alexakis, L., Fusaro, A., . . . Svartström, O. (2024). Avian influenza overview March–June 2024. *EFSA Journal, 22*(7), e8930.
- Bouzidi, H. S., Sen, S., Piorkowski, G., Pezzi, L., Ayhan, N., Fontaine, A., . . . Grard, G. (2024). Genomic surveillance reveals that the dengue 2 virus lineage responsible for the 2023-2024 epidemic in the French Caribbean Islands is resistant to Mosnodenvir. *bioRxiv*, 2024.2004. 2010.588695.
- Cobar, O., & Cobar, S. (2024). Omicron Variants World Prevalence, WHO COVID-19 Dashboard, ECDC Communicable Disease Threat Report, and CDC COVID Data Tracker Review. *World*.
- Klitting, R., Piorkowski, G., Rousset, D., Cabié, A., Frumence, E., Lagrave, A., . . . Fagour, L. (2024). Molecular epidemiology identifies the expansion of the DENV2 epidemic lineage from the French Caribbean Islands to French Guiana and mainland France, from 2023 to 2024. *Eurosurveillance, 29*(13), 2400123.
- Lvov, D. K., & Alkhovsky, S. V. (2024). To the 55th anniversary of the Department of Virus Ecology with the Scientific and Practical Center for the Ecology and Epidemiology of Influenza (DI Ivanovsky Institute of Virology of the NF Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of Russian Federation). *Problems of Virology, 69*(1), 7-21.
- Mironenko, A., Kravchuk, I., Radchenko, L., Teteriuk, N., Holubka, O., Bolotova, L., . . . Goy, A. (2024). Etiology of Four Waves of the COVID-19 Pandemic in Ukraine according to the SARS-CoV-2 Virus Genome Sequencing Data: A Pilot Study. *Microbiology Research, 15*(2), 994-1006.
- Rasmussen, A. L., Gronvall, G. K., Lowen, A. C., Goodrum, F., Alwine, J., Andersen, K. G., . . . Broadbent, A. J. (2024). Virology—the path forward. *Journal of virology, 98*(1), e01791-01723.
- Shanmugaraj, B. (2024). Ever-evolving SARS-CoV-2: The latest variant KP. 2 is on the rise. *Asian Pacific Journal of Tropical Medicine, 17*(6), 241-242.
- Vaughan, A. M., Afzal, M., Nannapaneni, P., Leroy, M., Andrianou, X., Pires, J., . . . Aberle, S. (2024). Continued circulation of pox: an epidemiological and phylogenetic assessment, European Region, 2023 to 2024. *Eurosurveillance, 29*(27), 2400330.
- Wreghitt, T., & Kudesia, G. (2024). *Clinical and diagnostic virology*: Cambridge University Press.